Blood Test Tracks Tumor DNA to Check Early Response in Solid Cancers
Studies circulating tumor DNA in blood to watch cancer response in adults with solid tumors.
Key facts
- Who runs it
- Washington University School of Medicine
- Where
- St Louis, United StatesSee the site
- Trial code
- Registry title
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 29 May 2019
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 2 groups
- Record updated
- 20 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adult donors to give samples for research on circulating tumor DNA (ctDNA) in solid tumors.
- Age
- 18 years or older
- Sex
- All sexes can join
Main reasons for not taking part
- Healthy donors younger than 18 years of age
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Eligible healthy donors will be at least 18 years of age
Who cannot take part
- Healthy donors younger than 18 years of age
Where in United States
- Washington University School of MedicineSt Louis, United StatesContact: Melissa Reimers, M.D.Taking people
About the trial
What the trial wants to find out
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
The 2 groups in the trial
- Healthy Donor Samples
* Donation of blood and/or urine samples as often as bi-monthly and as many as 24 times in total * These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise.
- Samples from Repository and Banking Studies
* Healthy prostate and/or blood and/or urine samples from Genitourinary Repository * Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies * Tissue and/or blood samples from Esophageal Repository * Tissue and/or blood samples from Genitourinary Repository * Tissue and/or plasma from Sarcoma Tissue Bank * Tissue and/or plasma from Breast Cancer Bank * Tissue, plasma, and/or urine from GI Tissue and Blood Bank * Tissue, blood, and/or urine from Solid Tumor Bank * Tissue, blood, and/or urine from Lung Cancer Bank * Tissue and/or blood from Skin Cancer Bank * Tissue and/or blood from Pediatric Neurosurgery Tissue Bank
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Plain-language title
- Blood Test Tracks Tumor DNA to Check Early Response in Solid CancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 February 2026